Literature DB >> 8652717

Contraceptive use and HIV infection in Kenyan family planning clinic attenders.

S K Sinei1, J A Fortney, C S Kigondu, P J Feldblum, M Kuyoh, M Y Allen, L H Glover.   

Abstract

This pilot study aimed to determine the feasibility of a larger study of contraception and risk of HIV infection in women. We also measured risk factors for and occurrence of HIV infection in the participants. A cohort of 1537 seronegative women attending a family planning clinic in Nairobi, Kenya was enrolled and followed for up to 12 months per woman. HIV testing was done quarterly. A nested case-control analysis was done with seroconverting women (cases) and 3 matched controls per case, who had detailed interviews and received physical examinations and STD tests. The prevalence of HIV at enrollment was 6.1%; seropositive women were excluded from further analysis. The 12-month life-table cumulative incidence of HIV was 2.1 per 100 women (95% confidence interval [CI] 1.1-3.2). In the nested case-control analysis (17 cases and 51 controls), the crude odds ratio of HIV infection comparing oral contraceptive (OC) users with other women was 3.5 (95%) CI 0.8-21.5), which persisted after control for single confounders at a time. The putative association between OC use sand HIV infection is critical to public health policy, yet no study has been conducted specifically to measure it, yielding weak and conflicting evidence. We intend to conduct a larger study with a similar design as the current pilot study, which confirmed the feasibility of a more definitive project.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Case Control Studies; Cohort Analysis; Contraception; Contraceptive Methods; Developing Countries; Diseases; Eastern Africa; English Speaking Africa; Evaluation; Family Planning; Follow-up Studies; Hiv Infections--women; Incidence; Kenya; Measurement; Oral Contraceptives; Prevalence; Research Methodology; Research Report; Risk Assessment; Studies; Viral Diseases

Mesh:

Year:  1996        PMID: 8652717     DOI: 10.1258/0956462961917104

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  7 in total

1.  Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling.

Authors:  Charles S Morrison; Pai-Lien Chen; Cynthia Kwok; Barbra A Richardson; Tsungai Chipato; Roy Mugerwa; Josaphat Byamugisha; Nancy Padian; David D Celentano; Robert A Salata
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

2.  Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies.

Authors:  Lauren J Ralph; Sandra I McCoy; Karen Shiu; Nancy S Padian
Journal:  Lancet Infect Dis       Date:  2015-01-09       Impact factor: 25.071

Review 3.  Sex steroid hormones, hormonal contraception, and the immunobiology of human immunodeficiency virus-1 infection.

Authors:  Zdenek Hel; Elizabeth Stringer; Jiri Mestecky
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

4.  Contraception choice for HIV positive women.

Authors:  H S Mitchell; E Stephens
Journal:  Sex Transm Infect       Date:  2004-06       Impact factor: 3.519

5.  Sexual risk factors for HIV infection in early and advanced HIV epidemics in sub-Saharan Africa: systematic overview of 68 epidemiological studies.

Authors:  Li Chen; Prabhat Jha; Bridget Stirling; Sema K Sgaier; Tina Daid; Rupert Kaul; Nico Nagelkerke
Journal:  PLoS One       Date:  2007-10-03       Impact factor: 3.240

Review 6.  Copper intrauterine device use and HIV acquisition in women: a systematic review.

Authors:  Philip C Hannaford; Angeline Ti; Tsungai Chipato; Kathryn M Curtis
Journal:  BMJ Sex Reprod Health       Date:  2020-01

Review 7.  An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women.

Authors:  Chelsea B Polis; Kathryn M Curtis; Philip C Hannaford; Sharon J Phillips; Tsungai Chipato; James N Kiarie; Daniel J Westreich; Petrus S Steyn
Journal:  AIDS       Date:  2016-11-13       Impact factor: 4.177

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.